The value of bone marrow imprint in diagnosis of plasma cell myeloma and monitoring the remission after chemotherapy

Abstract

Objective To investigate the value of bone marrow imprint in the diagnosis of plasma cell myeloma and the remission rate after chemotherapy. Methods Bone marrow aspiration, bone marrow imprint, and bone marrow biopsy of plasma cell myeloma with 128 patients were collected. The bone marrow biopsy was used as the standard. Bone marrow imprint was compared to bone marrow aspiration in bone marrow nucleated cells quantity, infiltration degree, and diagnostic coincidence rate. Sensitivity, specificity, positive predictive value, and Youden index were evaluated. Results The results of bone marrow imprint showed that the number of nucleated cells was better than that of bone marrow aspiration (P 0.05). Bone marrow biopsy combined with CD38 (+ ) showed the degree of infiltration of bone marrow as the standard, and the bone marrow imprint was better than that of bone marrow aspiration (P 0.05). To evaluate the compliance rate of bone marrow infiltration in bone marrow imprint: In phase I, the compliance rate of bone marrow aspiration was 95.83% (23/24) and bone marrow imprint of 91.67% (22/24), the difference was not statistically significant (P>0.05); In phase II, bone marrow imprint coincidence rate was 92.86% (65/70), which was significantly higher than that of bone marrow aspiration in 65.71% (46/70) (P<0.05); In phase III, bone marrow imprint coincidence rate was 79.41% (27/34), which was significantly higher than that of bone marrow aspiration in 44.12% (15/34) (P<0.05). The other parameters, such as sensitivity, specificity, positive predictive value, and Youden index were better than those of bone marrow aspiration. Conclusions Bone marrow imprint has characteristics that both bone marrow aspiration and bone marrow biopsy have. It has obvious advantages in diagnosis of plasma cell myeloma and monitoring the remission after chemotherapy. Key words: Bone marrow examination; Biopsy; Microtomy; Multiple myeloma/DI/DT